Drug approvals are no longer permanent guarantees of market tenure.
The regulatory victory of securing a drug approval is increasingly fragile, as agencies aggressively weaponize post-marketing confirmatory trials and safety reviews to claw back market access.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
An approved drug's market tenure is actively threatened as the FDA attempts to revoke its green light after discovering clinical trial errors.
The appearance of severe safety trade-offs in its confirmatory trial threatens to undo the market access secured under its accelerated approval.
European authorities recommended withdrawing Tavneos's approval because underlying trial data breaches compromised its established safety and efficacy profiles.
Discovery of trial irregularities and data manipulation has led both U.S. and European regulators to initiate processes to revoke Tavneos's approved status.
The failure of the confirmatory LAGOON study threatens to strip Zepzelca of its accelerated approval for second-line therapy.
A drug's post-market tenure is highly vulnerable as regulators leverage failed confirmatory outcomes to trigger potential market withdrawals.